Experienced in Autosomal Recessive Hypotrichosis

Neil E. Fleshner

700 University Avenue, 
Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Autosomal Recessive Hypotrichosis
700 University Avenue, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Neil Fleshner practices in Toronto, Canada. Mr. Fleshner is rated as an Experienced expert by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Prostate Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Cystectomy.

His clinical research consists of co-authoring 554 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autosomal Recessive Hypotrichosis.

Gender
Male

Locations

700 University Avenue, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: Apalutamide, Abiraterone Acetate, Prednisone, Docetaxel, Niraparib, Atezolizumab
Study Phase: Phase 2
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
Enrollment Status: Terminated
Publish Date: October 04, 2024
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer
Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2024
Intervention Type: Drug
Study Phase: Not Applicable
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Prednisone, Leuprolide, Cabazitaxel, Peg-filgrastim
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drugs: Dexamethasone, Radium-223 Dichloride
Study Phase: Phase 4
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial
A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial
Enrollment Status: Withdrawn
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
A Randomized Pilot Study of Conventional Versus Advanced Pelvic Floor Exercises to Treat Urinary Incontinence After Radical Prostatectomy
A Randomized Pilot Study of Conventional Versus Advanced Pelvic Floor Exercises to Treat Urinary Incontinence After Radical Prostatectomy
Enrollment Status: Completed
Publish Date: October 26, 2017
Intervention Type: Behavioral
Study Phase: Phase 1/Phase 2
A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy
A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy
Enrollment Status: Completed
Publish Date: August 23, 2017
Intervention Type: Behavioral
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

554 Total Publications

Corrigendum to "Magnetic Resonance Imaging (MRI)-Adapted Prostate Cancer Risk Tool Incorporating Cribriform and Intraductal Carcinoma" (Modern Pathology 2025 Dec;38(12):100852).
Corrigendum to "Magnetic Resonance Imaging (MRI)-Adapted Prostate Cancer Risk Tool Incorporating Cribriform and Intraductal Carcinoma" (Modern Pathology 2025 Dec;38(12):100852).
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fleshner's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile